Modern radiation therapy in part of treatment primary mediastinal (thymic) B-large cell lymphoma (results of 131 patients treated at N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation)
- Authors: Trofimova OP1,2, Zavodnova IZ1, Tumyan GS1,2, Pryamikova Y.I1, Volkova NV1, Zaichenko OS1, Nazarenko AV1
-
Affiliations:
- N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation
- Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation
- Issue: Vol 20, No 4 (2018)
- Pages: 5-15
- Section: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/29559
- DOI: https://doi.org/10.26442/18151434.2018.4.180142
- ID: 29559
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
O P Trofimova
N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation; Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation
Email: dr.Trofimova@mail.ru
д-р мед. наук, вед. науч. сотр. отд-ния радиологического, проф. каф. онкологии 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
I Z Zavodnova
N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation
Email: inga.ilyasova@gmail.com
врач-онколог отделения химиотерапии гемобластозов отдела гематологии и трансплантации костного мозга 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
G S Tumyan
N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation; Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation
Email: gaytum@mail.ru
д-р мед. наук, вед. науч. сотр. отд-ния химиотерапии гемобластозов, проф. каф. онкологии 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
Yu I Pryamikova
N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federationврач-радиотерапевт отд-ния радиологического 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
N V Volkova
N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation
Email: drvekova@mail.ru
врач-радиотерапевт отд-ния радиологического 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
O S Zaichenko
N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federationмедицинский физик отд-ния радиологического 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
A V Nazarenko
N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation
Email: llexoff@mail.ru
канд. мед. наук, зав. отд-нием радиологическим 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
References
- Сотников В.М. Лучевая терапия в современных программах лечения неходжкинских лимфом. Автореф. дис. … д-ра мед. наук. М., 1996. [ Sotnikov V.M. Luchevaia terapiia v sovremennykh programmakh lecheniia nekhodzhkinskikh limfom. Avtoref. dis. … d-ra med. nauk. M., 1996.]
- Виноградова Ю.Н. Значение лучевой терапии при химиолучевом лечении больных неходжкинскими лимфомами. Автореф. дис. … д-ра мед. наук. СПб., 2015. [ Vinogradova Iu.N. Znachenie luchevoi terapii pri khimioluchevom lechenii bol'nykh nekhodzhkinskimi limfomami. Avtoref. dis. … d-ra med. nauk. SPb., 2015]
- Трофимова О.П., Ткачев С.И., Юрьева Т.В. Прошлое и настоящее лучевой терапии в онкологии. Клин. онкогематология. 2013; 6 (4): 355-64. [Trofimova O.P., Tkachev S.I., Iur'eva T.V. Proshloe i nastoiashchee luchevoi terapii v onkologii. Klin. onkogematologiia. 2013; 6 (4): 355-64]
- Moller P, Lammler B, Herrmann B et al. The primary mediastinal clear cell lymphoma of B-cell type has variable defects in MHC antigen expression. Immunology 1986; 59 (3): 411-7. doi: 10.1007/bf00705408
- Bishop P.C, Wilson W.H, Pearson D et al. CNS involvement in primary mediastinal large B-cell lymphoma. J Clin Oncol 1999; 17 (8): 2479-85.
- Levitt L.J, Aisenberg A.C, Harris N.L et al. Primary non-Hodgkin’s lymphoma of the mediastinum. Cancer 1982; 50 (11): 2486-92. doi: 10.1002/1097-0142 (19821201)50: 11<2486: AID-CNCR2820501138>3.0.CO; 2-G
- Поддубная И.В. Российские клинические рекомендации по диагностике и лечению лимфопролиферативных заболеваний. Под ред. И.В.Поддубной, В.Г.Савченко 2016; с. 155-61. [ Poddubnaia I.V. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu limfoproliferativnykh zabolevanii. Pod red. I.V.Poddubnoi, V.G.Savchenko 2016; s. 155-61.]
- Hamlin P.A, Portlock C.S, Straus D.J et al. Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999. Br J Haematol 2005; 130 (5): 691-9. doi: 10.1111/j.1365-2141.2005.05661.x
- Rosenwald A, Wright G, Leroy K et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003; 198 (6): 851-62. doi: 10.1084/jem.20031074
- Jacobson J.O, Aisenberg A.C, Lamarre L et al. Mediastinal large cell lymphoma. An uncommon subset of adult lymphoma curable with combined modality therapy. Cancer 1988; 62 (9): 1893-8. doi: 10.1002/1097-0142 (19881101)62: 9<1893: AID-CNCR2820620904>3.0.CO; 2-X
- Zinzani P.L, Martelli M, Magagnoli M et al. Treatment and clinical management of primary mediastinal large B-cell lymphoma with sclerosis: MACOP-B regimen and mediastinal radiotherapy monitored by (67)Gallium scan in 50 patients. Blood 1999; 94 (10): 3289-93.
- Todeschini G, Ambrosetti A, Meneghini V et al. Mediastinal large-B-cell lymphoma with sclerosis: a clinical study of 21 patients. J Clin Oncol 1990; 8 (5): 804-8.
- Bertini M, Orsucci L, Vitolo U et al. Stage II large B-cell lymphoma with sclerosis treated with MACOP-B. Ann Oncol 1991; 2 (10): 733-7.
- Moskowitz C.H, Schöder H, Teruya-Feldstein J et al. Risk-Adapted Dose-Dense Immunochemotherapy Determined by Interim FDG-PET in Advanced-Stage Diffuse Large B-Cell Lymphoma. J Clin Oncol 2010; 28 (11): 1896-903. doi: 10.1200/JCO.2009.26.5942
- Savage K.J, Al-rajhi N, Voss N et al. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol 2006; 17 (1): 123-30.
- Dunleavy K, Pittaluga S, Maeda LS et al. Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma. New Engl J Med 2013; 368 (15): 1408-16. doi: 10.1056/NEJMoa1214561
- Zinzani P.L, Martelli M, Bertini M et al. Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. International Extranodal Lymphoma Study Group (IELSG). Haematologica 2002; 87 (12): 1258-64.
- Todeschini G, Secchi S, Morra E et al. Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B. Br J Cancer 2004; 90: 372-6. DOI: 10.1038/ sj.bjc.6601460
- Wang J, Liu X, Ma F et al. Role of radiotherapy in the treatment of primary mediastinal large B-cell lymphoma. Oncol Letters 2015; 10 (5): 2925-30. doi: 10.3892/ol.2015.3700
- Broccoli A, Casadei B, Stefoni V et al. The treatment of primary mediastinal large B-cell lymphoma: a two decades monocentric experience with 98 patients. BMC Cancer 2017; 1 (17): 1-8. doi: 10.1186/s12885-017-3269-6
- Smith D. Oncology 1998; 55: 284-8.
- Martelli M, Ceriani L, Zucca E et al. [18F]Fluorodeoxyglucose Positron Emission Tomography Predicts Survival After Chemoimmunotherapy for Primary Mediastinal Large B-Cell Lymphoma: Results of the International Extranodal Lymphoma Study Group IELSG-26 Study. J Clin Oncol 2014; 32 (17): 1769-75. doi: 10.1200/JCO.2013.51.7524
- Pinnix C.C, Dabaja B, Ahmed M.A. Single-Institution Experience in the Treatment of Primary Mediastinal B Cell Lymphoma Treated With Immunochemotherapy in the Setting of Response Assessment by 18Fluorodeoxyglucose Positron Emission Tomography. Int J Radiation Oncol Biol Phys. Series: Radiation and the Modern Management of Lymphoma 2015; 92 (1): 113-21. doi: 10.1016/j.ijrobp.2015.02.006
- Асланиди И.П, Мухортова О.В., Катунина Т.А. и др. Современные аспекты применения позитронно-эмиссионной томографии при лимфомах. Клин. онкогематология. 2015; 8 (1): 13-25. [ Aslanidi I.P, Mukhortova O.V., Katunina T.A. i dr. Sovremennye aspekty primeneniia pozitronno-emissionnoi tomografii pri limfomakh. Klin. onkogematologiia. 2015; 8 (1): 13-25.]
- Kuruvilla J, Pintilie M, Tsang R et al. Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma. Leukemia Lymphoma 2008; 49 (7): 1329-36. doi: 10.1080/10428190802108870
- The international non-hodgkin lymphoma prognostic factors project. NEJM 1993; 329: 987-94.
- Moormeier J.A, Williams S.F, Golomb H.M. The staging of non-Hodgkin's lymphomas. Semin Oncol 1990; 17: 43-50.
- Common Toxicity Criteria of National Cancer Institute, 2005.
- Cox J.D, Stetz J, Pajak T.F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 31 (5): 1341-6.
- ICRU Report 62: Prescribing, Recording and Reporting Photon Beam Therapy. Bethesda: International Commission on Radiation Units and Measurements - 1999.
- Emami B, Lyman J, Brown A et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. Series: Three-Dimensional Photon Treatment Planning Report of the Collaborative Working Group on the Evaluation of Treatment Planning for External Photon Beam Radiotherapy 1991; 21 (1): 109-22. DOI: 10.1016/ 0360-3016 (91)90171-Y
- Marks L.B, Yorke E.D, Jackson A et al. Use of Normal Tissue Complication Probability Models in the Clinic. Int J Radiat Oncol Biol Phys. Series: Quantitative Analyses of Normal Tissue Effects in the Clinic 2010; 76 (3). Suppl.: S10-S19. doi: 10.1016/j.ijrobp.2009.07.1754